[Market Focus] NextBioMedical Soars 9% on News of 'Nexphere-F' Entry into Japan
Shares of NextBioMedical are showing strong gains of over 9% following news of the company’s entry into the Japanese market.
As of 9:19 a.m. on April 10, 2026, NextBioMedical was trading at 66,300 won, up 5,500 won (9.05%) from the previous trading day.
On this day, NextBioMedical announced that it had signed a licensing agreement with Asahi Intecc, a global medical device company based in Japan, for the Japanese distribution rights of Nexphere-F, a vascular embolization-promoting prosthesis. Asahi Intecc is a specialized medical device company with a strong presence in global markets, including the United States, Europe, China, and India.
This contract was executed in the form of supplying finished products. Nexphere-F, the vascular embolization-promoting prosthesis, has received product approvals from the Ministry of Food and Drug Safety in Korea, the European Medical Device Directive (CE-MDD), and Health Canada. Post-marketing clinical trials are currently underway both domestically and internationally. Clinical trials for approval by the U.S. Food and Drug Administration (FDA) are also ongoing, with the goal of obtaining FDA approval.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Asahi Intecc plans to conduct clinical trials for Japanese PMDA approval of Nexphere-F, targeting patients suffering from certain chronic pain conditions.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.